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Igor M. Sauer  1, Johann Pratschke1, Moritz Schmelzle1 & Felix Krenzien  1,2
Nicotinamide adenine dinucleotide (NAD), a prominent member of the pyridine nucleotide family, plays 
a pivotal role in cell-oxidation protection, DNA repair, cell signalling and central metabolic pathways, 
such as beta oxidation, glycolysis and the citric acid cycle. In particular, extracellular NAD+ has recently 
been demonstrated to moderate pathogenesis of multiple systemic diseases as well as aging. Herein 
we present an assaying method, that serves to quantify extracellular NAD+ in human heparinised 
plasma and exhibits a sensitivity ranging from the low micromolar into the low nanomolar domain. 
The assay achieves the quantification of extracellular NAD+ by means of a two-step enzymatic cycling 
reaction, based on alcohol dehydrogenase. An albumin modified revised simulated body fluid was 
employed as standard matrix in order to optimise enzymatic activity and enhance the linear behaviour 
and sensitivity of the method. In addition, we evaluated assay linearity, reproducibility and confirmed 
long-term storage stability of extracellular NAD+ in frozen human heparinised plasma. In summary, 
our findings pose a novel standardised method suitable for high throughput screenings of extracellular 
NAD+ levels in human heparinised plasma, paving the way for new clinical discovery studies.
Nicotinamide adenine dinucleotide (NAD) is a pyridine dinucleotide omnipresent in all living cells either in oxi-
dised (NAD+), or reduced (NADH) form, whose ratio dictates the intracellular redox status and thus stipulates 
the overall cellular metabolic state1,2. Extracellular NAD+(eNAD+) was shown to exhibit important secondary 
messenger properties and acts to induce intracellular calcium release, thereby mediating lymphocyte chemot-
axis3. Interestingly, eNAD+ is known to be the result of either lytic release from injured tissue or non-lytic release 
mechanisms through pore forming proteins like connexin 43 (Cx43) hemichannels and is thus hypothesised to 
mediate immune response and organ function by means of paracrine signalling4–6.
Therapeutic applications of eNAD+ have been subject to extensive testing in murine models, with striking 
findings demonstrating anti-aging, regenerative and highly immunomodulatory traits7,8. For instance, Tullius 
et al.9, discovered that the systemic administration of β-NAD+ did not only block autoimmune encephalo-
myelitis induced paraplegia, but reversed disease progression through remyelination and neuroregeneration9. 
Furthermore, eNAD+ induced regulatory T cell differentiation, promoting allograft survival in a murine skin 
transplantation model with implications for concepts of alloimmunity and inflammatory diseases10. However, a 
significant lack of medical translation towards the study of eNAD+ in human disease is apparent.
In fact, the measurement of eNAD+ in different bodily compartments is challenging due to vast concentration 
variations. In human erythrocytes, intracellular NAD+ (iNAD+) was determined to be in the range of 10–40 M, 
whilst eNAD+ in pig plasma was found at a fraction of this concentrations, namely 240–290 nM11–13. Therefore, 
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analytical tests have to be inherently robust and span vastly different concentration ranges. High performance liq-
uid chromatography (HPLC) NAD+ analysis methods usually require any and all samples to be internally spiked 
with NAD+ and have struggled to quantify NAD due to signal masking and ionisation suppression, especially 
when followed by ultraviolet-visible (HPLC-UV) spectroscopic quantification14. However, HPLC methods fol-
lowed by mass spectrometry (HPLC-MS), and especially tandem mass spectrometry (HPLC-MS/MS), have man-
aged to achieve remarkable sensitivity and specificity for iNAD+ thanks to their ability to separate the respective 
metabolites through elution with highly specialised columns and successively combining the relaxation time of 
specific metabolites with their mass spectrum15. Generally, the entirety of the apparatus, namely the columns, the 
mass or UV spectrometer as well as the actual HPLC machine, required for HPLC analyses tends to come with a 
hefty price tag, rendering it prohibitively expensive for the general scientific community. Typically, each singular 
measurement of LC-based assays consumes significant amounts of time, from ten minutes up to one hour, mak-
ing their application to high throughput screenings impractical.
A promising concept enabling the measurement of minuscule analyte concentrations is known as enzymatic 
cycling, whereby a reactant recycling of the analyte takes place and is used to overproportionately amplify a 
redox indicator dye mediated signal, without the need for additional purification or concentration steps. First 
introduced by Warburg et al.16, the analysis of pyridine nucleotides was pioneered through an enzymatic cycling 
reaction17–19. In an effort to refine this method, Rhodes et al.20, used alcohol dehydrogenase for the cycling reac-
tion and quantification of pyridine nucleotides in cox orange apples20. Although this method relied on the fluori-
metric measurement of the highly red fluorescing resorufin, the reduced form of resazurin, the signal might be 
masked by the autofluorescence of plasma. In later years, ADH gained popularity and was subsequently adopted 
as the enzyme of choice, as it is present in all living organisms21–23. Nonetheless, the majority of these studies have 
been conducted to investigate iNAD+, and have not been validated for the study of eNAD+ in human plasma. 
Consequently, we established a method to meet the challenges of measuring eNAD+ in human plasma based 
upon known protocols13,20,24. More precisely, a heat based dichotomous pH extraction procedure was imple-
mented to extract purified versions of NAD+ or NADH, subsequently quantified by a colorimetric two-step 
enzymatic cycling assay18,25. The method’s sensitivity ranged from the low micromolar into the low nanomolar 
domain, using an albumin adjusted revised simulated body fluid (r-SBFA) as standard matrix in order to opti-
mise enzymatic activity and to increase assay linearity, providing a matrix closely resembling human plasma. 
The assay at hand satisfies common analytical standards of linearity, reproducibility and analyte storage stabil-
ity. Perspectively, this method is intended to meet the present scientific curiosity around and reveal the role of 
eNAD+ in immunological, oncological and systemic diseases.
Results
Evaluation of standard matrix and spectroscopy method. The standard matrix is one of the most 
crucial components of any assay, as its aim is to match the enzymatic cycling behaviour in plasma to that in the 
standards. Therefore it is crucial to the validity of the assaying method. In order to emulate the enzyme kinetics of 
ADH in human heparinised plasma and to gain assay sensitivity, several standard matrices were compared against 
human plasma, namely DEPC water, r-SBF and r-SBFA, using β-NAD Standards. Since a standard matrix might 
not be completely free of analyte, and, since human plasma endogenously features eNAD+, every standard matrix 
was accompanied by blanks produced from the same matrix. The resulting absorbance unit (AU) readings are 
presented in Fig. 1a, where all matrices were spiked with 50 μL of β-NAD standard S2 (376.8 nM). A qualitative 
inspection revealed that r-SBFA and heparinised plasma both presented with a highly linear increase, whereas 
DEPC and r-SBF. The absorbance increase reflects the enzyme velocity of ADH, and was highest in human hep-
arinised plasma, with an increase of approximately 1.95 AU over the course of 60 min and 1.84 AU for the run-
ner up, r-SBFA, concluded by 1.27 AU and 1.07 AU for DEPC and r-SBF, respectively. Analogously, the relative 
reaction velocity, vR, in plasma and r-SBFA were of remarkable resemblance, namely vRP = 0.0317 ± 0.0002 and 
vRA = 0.0306 ± 0.0002, respectively. All things considered, we found r-SBFA to best emulate in vivo-like enzyme 
kinetics of ADH, therefore adopting it as the standard matrix.
The advantages of fluorimetric over colorimetric detection techniques are well known and include a higher 
sensitivity and specificity as well as a lower limit of detection. Therefore, we evaluated whether a fluorimetric 
method was superior to the colorimetric method. For this purpose, MTT was used for absorbance and resazurin 
for fluorescence, both representing the signal generating molecules. Since the signal of interest arises from the 
fluorophore ejection from resorufin at a wavelength of 590 nm, an autofluorescence scan of both, the master mix 
(MM) and a human heparinised plasma sample was performed and a close-up view is given in Fig. 1b. Indeed, 
the relative autofluorescence spectra of the MM and plasma sample were found to differ only marginally from 
approximately 0.093 for the eNAD+ plasma sample and 0.057 for the MM, yielding a signal to noise ratio (SNR) of 
163%. The measured fluorescence unit (FU) and absorbance unit (AU) readings for β-NAD standards and human 
plasma are depicted in Fig. 1c,d. Despite the obvious parallelism of the colorimetric and fluorimetric standard 
traces of β-NAD at different concentrations, the reader is pointed to the apparent nullification of the fluorescence 
plasma signal. In contrast, the colorimetric detection method exhibited a strong signal for human plasma. In 
order to elucidate this surprising finding, that is, the apparent resorufin signal quenching in plasma, several auto-
fluorescence scans of the β-NAD standards, plasma samples and mastermix (please see methods) were conducted 
and are given in 1e and 1f. We further explored the fact that a signal was obtainable from the β-NAD stand-
ards, yet virtually absent from all plasma samples by comparing the autofluorescence spectra of the first β-NAD 
standard S1 (753.6 nM) to S1 spiked with a small (10 μL) quantity of plasma. Strikingly, the relative fluorescence 
signal at 590 nm was found to be 0.964 for S1 and 0.102 for the MM (945% SNR), which dropped sharply upon 
the addition of human plasma to 0.614, giving a 602% SNR. Note, the first emission spike around 320 nm from 
formulations containing either albumin or plasma is in fact due to the autofluorescence of albumin itself, since its 
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tyrosine side chains fluoresces at this specific wavelength26,27. Moreover, human blood plasma is known to exhibit 
substantial autofluorescence around 500–600 nm due to physiologically occurring porphyrins28–31.
In conclusion, we found the colorimetric method, displayed in Fig. 2, superior to the fluorimetric alternative 
concerning the measurement of eNAD+ in human heparinised plasma.
Reaction time scale and eNAD+ storage stability. To determine the time frame of the assay’s linear 
operation, the absorbance readings for β-NAD standards S1 (753.6 nM) to S6 (23.5 nM) are depicted in Fig. 3a. 
Clearly, the relative reaction velocity, vR, of S1 decreased, adopting a fluctuating and turbulent behaviour after 
about min 30, as seen in Fig. 3b,c, with the latter displaying the derivative of vR, aR. From this, we determined the 
time frame of linear operation between min 5–25 of reaction time.
The stability of eNAD+ in human plasma remains an elusive and vague topic of investigation, suffering 
from a substantial lack of literature. However, eNAD+ can be hydrolysed or degraded by multiple enzymes in 
Figure 1. Overview of the spectroscopic techniques. (a) Comparison of the assay dynamics in different standard 
matrices utilising the absorbance unit (AU) readings obtained from DEPC water, revised simulated body fluid 
(r-SBF), revised simulated body fluid adjusted with albumin (r-SBFA) and human plasma, all spiked with 50 μL 
of 376.8 nM β-NAD standard (S2). (b) Fluorescence scan of the autofluorescence of the Master Mix (MM) 
and a NAD+ sample as prepared in the actual assay reaction, scanned from λex1 = 280 nm − λex2 = 850 nm in 
steps of Δλ = 2 nm. The  resorufin signal is indicated at λ = 590 nm in the detail view. (c) Enzyme dependent 
assay kinetics for β-NAD standards S1–S6 including a heparinised plasma sample and the blank of a given run 
using the fluorimetric method. (d) Enzyme dependent assay kinetics for β-NAD standards S1–S6 including 
a heparinised plasma sample and the blank of a given run using the colorimetric method. (e) Fluorescence 
scan of the autofluorescence of the Master Mix (MM) and β-NAD standard S1 as prepared in the actual assay 
reaction (S1 + r-SBFA + MM), scanned from λex1 = 280 nm − λex2 = 850 nm in steps of Δλ = 2 nm. (f) Visual 
representation of the resorufin quenching effect that occurs when a minuscule amount of heparinised plasma 
sample is added to the β-NAD standard S1.
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plasma, such as ADPribosyltransferases (ARTs), as well as NAD+ - dependent glycohydrolases (NADases)32,33. 
Likewise, the knowledge of analyte storage stability remains crucial for investigational studies. Therefore, we 
tested eNAD+ storage stability in human heparinised plasma samples at −80 °C over the course of three months, 
which is displayed in Fig. 3d. Indeed, no statistically significant difference was found between any of the measured 
time-points, at a significance level of p < 0.01, with the measured eNAD+ concentration being (225.9 ± 16.7) nM. 
Hence, eNAD+ can be considered stable in frozen human heparinised plasma for at least three months at −80 °C. 
These results were found to be in accordance with a murine study that demonstrated stability of eNAD+ in frozen 
murine plasma for at least one week and the commercially available β-NAD, which was described to be stable for 
at least six months in aqueous solution15,34.
Recapitulating, linear enzymatic behaviour was confirmed for min 5–25 of the assay reaction time and eNAD+ 
was found to remain stable in frozen human heparinised plasma for at least three months.
Figure 2. NAD+ cycling principle. Schematic representation of the enzymatic alcohol dehydrogenae (ADH) 
cycling principle used to measure eNAD+, involving phenazine methosulfate (PMS) as the primary and 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as the secondary redox indicator dye. The 
method was inspired by the findings of Rhodes et al.20 and adjusted with insights from the research of Zhu  
et al.24 and O’Reilly et al.13.
Figure 3. NAD+ assay and storage. (a) Enzyme dependent assay kinetics for β-NAD standards S1–S6 
and the blank of a given run during the assay validation: S1 (753.6 nM), S2 (376.8 nM), S3 (188.4 nM), S4 
(94.2 nM), S5 (47.1 nM), S6 (23.5 nM), whilst standards S7 (11.8 nM) and S8 (5.6 nM) were omitted. (b) 
Relative reaction velocities (vR) of standards S1–S8 during min 5–40 of the assay reaction. n = 8. (c) Relative 
reaction accelerations (aR) of standards S1-S8 during min 5–40 of the assay reaction. n = 8. (d) Measured 
NAD+ concentrations in human heparinised plasma stored at −80 °C for a given amount of time. No statistical 
significance was found when comparing the measured timepoints to the baseline (d = 0). n = 6. Statistics: Two-
tailed, unpaired t-test with the confidence limits of CL = 99%, as well as a two-way ANOVA (without repeated 
measures) adjusted with Tukey’s multiple comparisons test featuring CL = 99%. A significance level of p < 0.01 
was applied to reject the null hypothesis. All error bars are given in terms of ±SD.
www.nature.com/scientificreports/
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Standard linearity and enzyme kinetics. In order to accurately measure eNAD+, it is a fundamental 
requirement that the vR ratio of any two standards behaves identical to the ratio of their β-NAD concentrations. 
To examine this, the vR ratio of standard, n, and neighbour n + 1, was defined to be:
γ = +v v/ (1)n Rn Rn1
The calculated results are presented in Fig. 4a. One can observe that γ remained relatively constant and closely 
resembled the 50% β-NAD standard dilutions for S1 (753.6 nM) to S7 (11.8 nM), with γ1 = 0.556 ± 0.011 to 
γ6 = 0.501 ± 0.052 and corresponding relative errors of δ = .γ 1 96%1  and δ = .γ 10 3%6 . However, there was an evident drop in the ratio when considering the change from S7 to S8 (5.9 nM), to γ7 = 0.385 ± 0.083, where the relative 
error increased to δ = .γ 21 6%7Moreover, NAD+ was employed as the new substrate in the double reciprocal Lineweaver-Burke plot35. The 
data displayed in Fig. 4b was constructed from eight independent assay reactions, where the Michaelis-Menten 
constant was found to be Km = (115 ± 45.6) nM in addition to the maximum reaction velocity being 
= . ± . μ −v (8 58 3 13) mol minmax
1.
In summary, the linear relationship between the standard slopes (γ) was confirmed for S1 (753.6 nM) down to 
S7 (11.8 nM), covering sufficiently the range of anticipated physiological concentrations of eNAD+13.
Reliability of NAD+ detection in relation to albumin. Physiologically, serum albumin is the most 
abundant protein of human plasma. Patients with liver diseases can suffer from hypoalbuminaemia, presenting 
with levels below 35 g/L and drastic inter- as well as intrapatient variability, while healthy subjects typically feature 
levels in the range of 35–50 g/L. Hence, we studied the effect of varying albumin concentrations on the assay’s 
predictive capability. As illustrated shortly, an ordinary regression line that runs not through the origin (nTTO, 
vR = mx + vb), as opposed to a regression line through the origin (TTO, ′vR = mx + 0), is subject to an inversely 
Figure 4. NAD+ assay linearity and enzyme kinetics. (a) The ratio of the slope (vR) of two sequential β-NAD 
standards, (n) and neighbour (n + 1), is given by γn between min 5–25 of the assay reaction. n = 8. (b) The 
Lineweaver-Burk Plot constructed for averaged, blank corrected, vR data from eight Runs including S1–S6. 
n = 8. Statistics: All error bars are given in terms of ±SD.
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proportional relationship between the albumin concentration of the matrix and the calculated eNAD+ value, 
rendering it unworkable for analysis.
In order to demonstrate this, we evaluated various r-SBFA matrices featuring 0 g/L (r-SBF), 10 g/L, 20 g/L, 
30 g/L and 40 g/L of albumin. In fact, one can observe from Fig. 5a, where nTTO and TTO calibration curves are 
contrasted, that their slopes remained relatively constant with varying concentrations of albumin for 
= . ± . − −m (1 50 0 10)ngAUmL min1 1 and ′ = . ± . − −m (1 51 0 12)ngAUmL min1 1, respectively. The individual values 
for the slopes of the nTTO and TTO approach are displayed more precisely in Fig. 5b. Here, no statistically significant 
differences between the neighbouring slopes of the physiological range of albumin concentrations (10–40 g/L) was 
found. However, Fig. 5a clearly demonstrates that an increase in the albumin concentration in the standard matrix 
caused an upward shift of the y-axis intercept, vb, for lines constructed with a nTTO approach and is numerically pre-
sented in Fig. 5c, where the baseline can be seen to vary from = − . ± . − −v ( 9 40 3 81)pgAUmL minb0
1 1 for no albumin 
(0 g/L) up to = . ± . − −v (4 31 12 6) ngAUmL minb40
1 1 for 40 g/L of albumin, with an average value of 
= . ± . − −v (4 31 12 6) ngAUmL minb
1 1, indicating a relative error of δ = 293%vb . No significant difference was found between vb40 and vb30 (p = 0.0193) as well as vb30 and vb20 (p = 0.0289), while vb20 and vb10 were, in fact, significantly dif-
ferent (p = 0.0016). Figure 5d reveals that the TTO method resulted in an average sample NAD+ concentration of 
x′ = 193 ± 17.0 nM, indicating a relative error of δx′ = 8.8% in contrast to x = 183 ± 47.4 nM for the nTTO approach, 
presenting with an escalated relative error of δx = 25.9%. Moreover, the TTO approach was fitted with an ordinary least 
squares regression, with CL = 99%, to produce y′ = −x0.34 nML/g + 194 nM (R2 = 0.7706), whilst the nTTO method 
featured y = −x2.84 nML/g + 237 nM (R2 = 0.9785), representing an approximately 8 times higher dependence of esti-
mated eNAD+ on albumin. When measuring the estimated eNAD+ amounts, the TTO method far outperformed the 
nTTO method. Merely a concentration of 30 g/L of albumin let to an insignificant increase of the estimated eNAD+ 
(p = 0.0361), whilst 20 g/L (p = 0.0049) and 10 g/L (p = 0.0007) of albumin caused significantly different predicted 
eNAD+ results. On the other hand, this effect was dampened when the TTO method was used as no significantly dif-
ferent estimated eNAD+ concentrations were quantified at any of the given albumin concentrations, since p < 0.01.
Figure 5. Albumin dependency of the assay. (a) Comparison of the calibration working curves not through the 
origin (nTTO, dotted) and to through the origin (TTO, solid) with respect to a varying albumin concentration 
in the β-NAD standards S1 (753.6 nM) through S6 (23.5 nM) of 0 g/L for the lowermost trace, 10 g/L, 
20 g/L, 30 g/L and 40 g/L for the uppermost trace. n = 3. (b) Comparison of the slopes, m, of the calibration 
working curves obtained by linear regression analyses nTTO (dark) and to TTO (light) for different albumin 
concentrations. n = 3. (c) Variance of the y-axis intercept, vn, of the regression lines nTTO with respect to 
varying albumin concentrations. n = 3. (d) Predicted pooled human heparinised sample eNAD+ concentrations 
using calibration working curves constructed nTTO (dark) and to TTO (light) with respect to varying 
albumin concentrations. A regression fit over the physiological range of albumin concentrations yielded 
y = −2.84 xnML/g + 236.5 nM (R2 = 0.9785) for the nTTO and y′ = −0.34 xnML/g + 194 nM (R2 = 0.7706) for 
the TTO approach. n = 3. Statistics: Two-tailed, unpaired t-test with the confidence limits of CL = 99%, where 
a significance level of p < 0.01 was applied to reject the null hypothesis. **p < 0.01. All error bars are given in 
terms of ±SD. The dotted line represents the physiological range of albumin concentrations.
www.nature.com/scientificreports/
7SCIEntIfIC REPORTS |         (2018) 8:16110  | DOI:10.1038/s41598-018-34350-6
Taken together, differing serum albumin levels cause inaccurate estimations of sample eNAD+ concentrations 
when the nTTO method is used. Strikingly, this effect was virtually eliminated, when calibration was constructed 
TTO, which lead to a substantially lower relative error as well as albumin related estimation bias.
Reproducibility, Sensitivity and Calibration. For the sake of evaluating the repeatability and robustness 
of the assay, the complete method was independently carried out eight times, with the respective slopes of the 
standard curves calculated within the interval of min 5–25 of the reaction time. The corresponding results are 
given in terms of the relative reaction velocity for each β-NAD standard n, vRn, and are displayed in Fig. 6a. In 
descending order the relative reaction velocities of standards S1 (753.6 nM) to S8 (5.9 nM) as well as the blanks 
were determined to be vR1 = (9.10 ± 0.28) × 10−4 AU/min for S1 down to vRS8 = (6.84 ± 0.42) × 10−5 AU/min for 
S8 and vRB = (6.18 ± 0.33) × 10−5 AU for the blank. The use of a two-way ANOVA (without repeated measures), 
adjusted with Tukey’s multiple comparisons test, revealed that there was no significant difference observable 
between S6 (23.5 nM) and S7 (11.8 nM, p = 0.012), S7 and S8 (5.9 nM, p = 0.373), S7 and the blank (p = 0.013), or 
S8 and the blank (p = 0.876). In order to examine the potential implications for the precision of the assay when an 
additional β-NAD standard, n−1, was used for calibration, the ratio of the standard deviation, σ, to the difference 













The respective values for ε are depicted in Fig. 6b, where the resolution error introduced by the consideration 
of S1 through S6 was found to be below ε1–5 < 20%, whereas the inclusion of S7 (11.8 nM) and S8 (5.9 nM) lead to 
an escalated resolution error of ε6 = 30% and ε7 = 70%, respectively. Having defined a threshold value of ε = 20%, 
S7 and S8 were discarded from the assay for their lack of a statistically relevant vR and inflation of ε.
Following this discovery, an ordinary least squares linear regression fit of the blank adjusted standard calibra-
tion curve was constructed from S1–S6 to run through the origin (TTO), shown in Fig. 6c, where ρ = 0.9984 and 
R2 = 0.9969, with the corresponding slope = . ± . − −m (1 75 0 04)ngAUmL min1 1.
In order to present clinical findings of eNAD+ concentrations in blood plasma, we obtained heparinised 
blood samples from 10 fasting patients, who were scheduled to receive hernioplasty. Subsequent to obtaining 
the plasma samples, we determined the eNAD+ value to have a mean concentration of (305.2 ± 32.2) nM (range: 
Figure 6. NAD+ assay reproducibility. (a) Mean relative reaction velocities (vR) for β-NAD standards S1 
(753.6 nM) through S8 (5.6 nM) and the blank measured between min 5–25 of the assay reaction. n = 8. (b) The 
ratio (εn) of standard deviations (σn), to the difference in relative reaction velocity (vR) of two sequential β-NAD 
standards, (n) and neighbour (n + 1), represented by ψn. n = 8. (c) Calibration working curve constructed from 
the average slopes (vR) of β-NAD standards S1 (753.6 nM) through S6 (23.5 nM), obtained from the eight-
fold assay repetition. n = 8. (d) Blood samples were taken from patients scheduled to undergo hernioplasty 
and analysed for their eNAD+ concentration. Statistics: n = 10. Among the analysed, there were 8 male and 2 
female patients, where the mean age averaged (52.1 ± 15.8) years, ranging from 29 to 75 years. The underlying 
diseases were inguinal hernia (n = 7), epigastric hernia (n = 1), hiatal hernia (n = 1) and umbilical hernia 
(n = 1). The overall average is displayed. Statistics: Two-way ANOVA (without repeated measures) adjusted with 
Tukey’s multiple comparisons test with CL = 99%. A significance level of p < 0.01 was applied to reject the null 
hypothesis. ****p < 0.0001. All error bars are given in terms of ±SD.
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240.9–342.7 nM). The graphical representation of this data is given in Fig. 6d. What is more, the analysis of one 
samples that was carried along all of the eight runs, resulted in a relative error of δ = 8% in the measured eNAD+ 
concentration.
When combining these results, the method was able to sense eNAD+ in human heparinised plasma and in 
standards featuring concentrations of 753.6 nM (S1) down to 23.5 nM (S6) maintaining a striking calibration 
precision yet exhibiting a minor relative error.
Discussion
In this study, we established a reliable and robust colorimetric two-step enzymatic cycling assay to quantify 
eNAD+ in human heparinised plasma, which can be used for high throughput screening of eNAD+ levels in 
clinical discovery studies. The assay quantifies eNAD+ by means of a two-step enzymatic cycling reaction, based 
on ADH (Fig. 2). An albumin modified r-SBF was used to warrant physiological enzymatic activity. In addition, 
we evaluated assay linearity, reproducibility and confirmed long-term storage stability of eNAD+ in frozen human 
heparinised plasma.
However, the correct blood collection method is of the essence. We employed lithium heparin tubes during 
the acquisition of blood samples as the common chelating agent K3EDTA is in fact a potent inhibitor of ADH, 
and would therefore eradicate linear enzyme behaviour36. In order to secure optimal enzyme activity, the concen-
trations of ADH as well as its substrate, ethanol, were chosen to be well beyond their point of saturation, so that 
any effect of even an ever so slight variation in their respective amounts would be essentially nullified24.
In order to validly calculate eNAD+ levels in human plasma, it was imperative to employ an appropriate and 
in vivo-like standard matrix. Physiologically speaking, albumin is the most abundant plasma protein, with a 
concentration in the range of 35–50 g/L, whilst being the main carrier of zinc in blood, as approximately 80% of 
all plasma zinc is bound to albumin37. Thus it serves as a major zinc donor in blood, comprising part of the so 
called exchangeable pool, which, given zinc’s role as a blood trace element, is crucial to the proper functioning 
of ADH. In fact, a catalytic zinc ion binds to ADH’s Cys-43, Cys-153 and His-66 amino acid residues, which was 
the primary rationalisation for our addition of albumin into r-SBF, since zinc is neither present in r-SBF, nor in 
DEPC38. This could very well explain the evident deviation from linearity after about 30 min in all zinc-free matri-
ces, indicating a decreased ADH reaction speed and successive plateauing substrate conversion rate. However 
this was alleviated through the addition of 40 g/L of albumin to r-SBF, as demonstrated in Fig. 1. Indeed, we 
hypothesise that, under the assumption that albumin’s affinity for zinc is not infinitely large, some of these zinc 
ions will be competed for, and eventually be seized by ADH. In addition, the extreme pH milieus, combined 
with the heat incubation upon pyridine extraction, will cause a release of zinc from albumin, facilitated by its 
denaturation. Results obtained from the comparison of different standard matrices, presented in Fig. 1a, seem to 
corroborate this hypothesis, for r-SBFA replicated the assay kinetics observed in human heparin plasma almost 
indiscriminately.
Moving on to the analyte isolation, a heat based dichotomous pH extraction procedure was utilised to extract 
and amass purified versions of either NAD+ at pH 1.5 or NADH at pH 12.5, as can be seen in Table 5, in con-
sideration of Lowry et al. and Lilius et al.18,25. An illustration of this process is given in Supplementary Fig. S.2. 
As the assaying method was intended to quantify eNAD+ plasma levels in exploratory studies, it was neces-
sary to test storage stability of eNAD+ in human heparinised plasma at −80 °C. This was done to evaluate the 
possibility, that eNAD+ would be hydrolysed by ectoenzymes from the family of NADases such as CD38 or 
ADPribosyltransferases like ART25,39. Subsequently, we confirmed the stability of eNAD+ in frozen human 
plasma for at least three months, which was in accordance with a murine study that demonstrated its stability for 
at least one week, as well as the known stability of β-NAD in aqueous solution for at least six months15,34.
With respect to the fluorimetric evaluation as an alternative quantification method, the reader is pointed to 
some potentially detrimental properties of human blood plasma that hinder the measurement of eNAD+ using 
resazurin. First and foremost, naturally occurring porphyrins cause the autofluorescence of human blood plasma 
to exhibit two prominent spikes at 630 nm and 590 nm, of which the latter one happens to be at the exact fre-
quency resorufin fluoresces at28. It is further known that these autofluorescence spectra can vary substantially over 
the range of 500–600 nm, due to immense variations in plasma porphyrin levels, which are common in patients 
with cancer29–31. What is more, another biological molecule with a broad autofluorescence band around 500–
600 nm is bilirubin40. The vast fluctuations in bilirubin levels, especially in patients suffering from liver disease 
can therefore cause significant baseline shifts that are very difficult to correct for. Having used resazurin instead 
Reagent Q (μmol) Well (μL) Plate (μL)
TEA 25.72 33.6 3528
EtOH 129 7.5 788
PMS 0.4 12.3 1292
MTT 0.1 41.4 4347
DEPC — 41.1 4316
ADH 125 U 14.4 1512
Table 1. List of materials used for the preparation of 150 μL master mix per well, scaled to fit a standard 96 
well plate (where 105 wells are considered necessary for the use of a pipetting basin). Note that the reagents 
employed are the products of this protocol so far, and have thus been preciously diluted and weighed into DEPC 
water.
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of MTT, we immediately realised the almost complete eradication of the signal in plasma, whilst the standards 
remained readily quantifiable. Moreover, we tested the impact of adding a small amount of a plasma sample to 
the first β-NAD standard, S1, upon which its obtained signal experienced a sharp drop, clearly demonstrated 
in Fig. 1e,f. Besides the aforementioned reasons, a few possible explanations are herein presented that could be 
responsible for this apparent quenching of the resorufin signal at the 590 nm emission band. In fact, Montejano et 
al.41 described that resorufin is quenched by quinones at this very frequency band41. Given the endogenous nature 
of these molecules, the sharp drop in resorufin’s fluorescence upon the addition of a small plasma quantity (which 
even contained physiological eNAD+ concentration) supports this hypothesis and explains why eNAD+ is not 
measurable in a full plasma sample via fluorescence spectroscopy.
In comparison to other measuring procedures of NAD+, it has to be stated that eNAD+ has been studied 
in a far lesser extent than iNAD+, most likely for its drastically reduced concentration, from 10–40 M intra-
cellularly to 240–290 nM extracellularly, which presents nontrivial analytical challenges11–13. Alternative to the 
quantification of chromogenic or fluorescent signals, the concentration of iNAD+ has been measured using a 
multitude of sophisticated high-performance liquid chromatography (HPLC) methods such as HPLC-UV42,43, 
as well as HPCL-NMR44,45, whilst, in a more specialised scenario, HPLC-UV11,46 and HPLC-MS47,48, have been 
employed to evaluate murine erythrocyte intracellular NAD+ (iNAD+) levels. These methods have been used 
predominantly to measure iNAD+, while only very few could be used to study eNAD+ directly without any 
preceding concentrating steps, for their relatively high limit of quantification. However, Liang et al.15 used a 
modified version of the HPLC-MS, namely the electrospray ionisation HPLC-ESI-MS to successfully measure 
eNAD+ in murine blood15. Nonetheless, for all analytical methods involving calibration methods, the standard 
matrix has to exhibit comparable traits to the authentic biological sample matrix and should either be a laboratory 
prepared or analyte-stripped version of the matrix of interest. In fact, Liang et al.15 used HPLC grade water in 
their HPLC-ESI-MS analysis, which seemed to be common practice amongst other HPLC based analyses15. This 
opens up the analysis of NAD+ to be subject to significant signal distortions through imperfect enzyme kinetics, 
signal masking by other analytes or by means of ionisation suppression14. In addition, the apparatus required for 
HPLC analyses tends to be rather expensive, therefore limiting their availability to the general scientific commu-
nity, whereas our enzymatic cycling method merely required an ordinary microplate reader, present in virtually 
all laboratories by default, in addition to any kind of transparent 96 well plate.
When it comes to plasma compounds that could affect the assays performance, we postulate that ADH is the 
main source of measurement variation, as it represents the main rate limiting factor in the redox dye conversion 
reaction. For instance, human isoforms of ADH are generally inhibited by common drugs such as aspirin or 
H2 receptor blockers in the form of cimetidine or ranitidine49,50. These drugs might be present in the plasma of 
individual patients at distinct concentrations. What is more, these drugs might very well resist, in part, the extrac-
tion, neutralisation and deproteinisation steps, thereby modulating the activity of ADH in the assay reaction. 
This could cause eNAD+ measurement variations at an inter- as well as intrapatient levels. ADH is characterised 
further through a modulatory effect by different hormones, such as growth hormones, epinephrine or estro-
gens which act in a stimulatory manner, while thyroid hormones51 and androgens can inhibit ADH’s activity52,53. 
Therefore, varying baseline levels of these hormones upon blood collection could further impact the behaviour 
of ADH in the plasma sample. However, this assumption seems to be more theoretical as the extraction step (60 
heat incubation for 10 min at pH 1.5) is expected to denature virtually all proteins and hormones. It is well known 
that ADH features broad specificity to aliphatic alcohols other than ethanol. For instance, it oxidises methanol to 
produce formaldehyde. In fact, methanol is of varying concentration in human blood, partly due to dietary pref-
erences for artificial sweeteners such as aspartame54. Fasting blood levels of methanol were found to be on average 
168 μmol/L, which converts to 5.39 mg/dL55. However, the assay procedure will cause a 6-fold dilution of meth-
anol levels, yielding an approximate concentration 1 mg/dL, which is less than 1% of the ethanol concentration 
in the MM (being 125 mg/dL). Furthermore, ADH can also metabolise retinol (Vitamin A), which is present in 
blood plasma at levels around 60 μg/dL56. It is due to the fact that ethanol’s concentration, as key substrate of ADH 
in the MM, was chosen to lie well beyond the point of saturation, that neither methanol nor retinol are expected 
to have a prominent effect on the measured eNAD+, for their minuscule concentrations. In summary, we hypo-
thethise that hormones, proteins and vitamins endogenous to human blood, will produce merely negligible effects 
on the assay, thanks to the selection of our extraction and neutralisation procedure, which provides an immensely 
harsh environment that most of these compounds cannot withstand.
The presented method was exhaustively tested in human heparinised plasma and the analysis as well as the 
experimental protocol, attached to this article as Supplementary Method S.1, account for immense variations 
in the standard and sample matrices, due to albumin fluctuations. In respect of the findings displayed in Fig. 5, 
it was evident that a regression line TTO would be used for all measurements, as it first and foremost increased 







Table 2. List of β-NAD standards prepared in DEPC water with respective concentrations.
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the robustness of the method and secondly it was simply not feasible to produce a tailored albumin blank for 
every human heparinised plasma sample due to practical reasons. Moreover, albumin concentrations are rarely 
known, as they are not covered by standard blood chemistry tests. This, is as the evidence gathered and presented 
in Fig. 5a,c, illustrates the high dependency of the y-axis intercept, vb, of the assay’s nTTO calibration curve on 
the albumin concentration of the standard matrix. Hence, when utilising those calibration curves to estimate the 
eNAD+ of an actual plasma sample, one will obtain very uncertain and unreliable results, as vb in the equation 
of the regression line, when extrapolating for an unknown amount, x, takes the role as a subtractor of vR, and, 
given that we are dealing with relatively small values of m in the denominator, causes escalated fluctuations of the 
resulting value. On a critical note, an estimation of the random error that arise when preparing the standards and 
the total random error, including the final addition of the MM to the standard, are given below. For this purpose, 
the common propagation of uncertainty analysis was conducted, where pipetting as well as applicable preparation 
errors, such as weighing scale or glassware uncertainties, were considered. For any given measurement of the 
experimental factors a, b and c resulting variable, Q, that is the combination of sums and differences, a + b, Q = a 
+ b − c, the uncertainties, Δ, add in quadrature, that is;
Q a b c( ) ( ) ( ) (3)2 2 2∆ = ∆ + ∆ + ∆
On the other hand, if R, is the resulting variable of a multiplication or division, = +R a b
c
, then the fractional 






























In fact, this resulted in the estimation of the random relative error in preparing S1 of δS1 = 4.84%, increasing 
to δS6 = 5.20% for S6, while the total relative error after the addition of the MM for S1 was determined to be 
δT1 = 8.29%, increasing to δT6 = 8.50% for S6. Obviously, this error can be minimised by preparing reagents in 
aliquots, where possible.
On a practical note, experimenter is able to perform the whole method given in Supplementary Method S.1, 
in approximately 90 min. When employing a commonly used 96 well plate this would imply a total experiment 
time of roughly 1 min per sample, representative of a substantial increase in time efficiency when compared to the 
commonly employed HPLC quantification methods, that usually require 10–60 min of reaction time per sample 
analysed.
At a molecular level, eNAD+, has been identified to be of intricate involvement in a substantial number of 
regulatory pathways as a coenzyme for ADPribosyltransferases (ARTs), NAD+-dependent protein deacetylases 
of the Sir2 family (SIRTs) as well as NAD+-dependent glycohydrolases (NADases), in addition to serving as a pre-
cursor of the calcium mobilising molecule cADPR (cyclic ADP-ribose)32,33,57. The highly modulating properties 
Reagent Supplier Amount (g)
NaCl SIGMA, USA, Catalog No: DE71376 5.403
NaHCO3 SIGMA, USA, Catalog No: DES5761 0.740
Na2CO3 SIGMA, USA, Catalog No: DES7795 2.046
KCl ROTH, GER, Catalog No: 6781.1 0.225
KH2PO4 ROTH, GER, Catalog No: 3904.1 0.138
MgCl2⋅6H2O ROTH, GER, Catalog No: HN03.1 0.311
HEPES ROTH, GER, Catalog No: 9105.4 11.928
CaCl2⋅2H2O ROTH, GER, Catalog No: HN04.1 0.388
Na2SO4 SIGMA, USA, Catalog No: S6547 0.072
BSA SERVA, GER, Catalog No: 47330.03 40
Table 3. List of materials used for the preparation of 1000 mL of a revised simulated body fluid adjusted 
with albumin (r-SBFA) where the pH was adjusted to be 7.5, using approximately 0.8 mL 1.0 N NaOH. The 
composition of the r-SBF without albumin was adopted from Oyane et al.63.
Formulation Na+ K+ Mg2+ Ca+ Cl− HCO3− HPO4− SO4− Buffer
Blood Plasma 142.0 5.0 1.5 2.5 103.0 27.0 1.0 0.5 —
Original SBF 142.0 5.0 1.5 2.5 148.8 4.2 1.0 0.0 Tris
Corrected (c-SBF) 142.0 5.0 1.5 2.5 147.8 4.2 1.0 0.5 Tris
Revised (r-SBF) 142.0 5.0 1.5 2.5 103.0 27.0 1.0 0.5 HEPES
Modified (m-SBF) 142.0 5.0 1.5 2.5 103.0 10.0 1.0 0.5 HEPES
Table 4. Common simulated body fluids compared to human blood plasma, where ionic concentrations are 
given in mM. The table was extracted from the findings of Oyane et al.63.
www.nature.com/scientificreports/
1 1SCIEntIfIC REPORTS |         (2018) 8:16110  | DOI:10.1038/s41598-018-34350-6
of eNAD+ are, on this note, underscored by its substantial involvement in highly specific and selective ectoen-
zymes, namely NADases such as CD38, ADPribosyltransferases like ART2 or its key role in purinergic signalling 
through P2X7 or P2Y5,39,58. Leading on to the systemic involvement of eNAD+ in immunological processes and 
its relevance to human physiology, the plasma membrane of eukaryotic cells was long believed to be impermeable 
to NAD+. Yet, after some initial findings of passive pyridine nucleotide transmembrane-transport, Bruzzone et 
al.59, successfully identified this elusive NAD+ transporter as the hexametric hemichannel Cx4359. Cx43 is a ubiq-
uitous transmembrane protein, that, when juxtaposed on adjacent cells, forms local high density areas at the gap 
junctions between these cells60.
In conclusion, we herein present a robust method for the measurement of eNAD+ in human heparinised 
plasma standardised, validated and optimised for low-cost high throughput screening applications using 
off-the-shelf materials, including standard laboratory equipment such as microplate readers. This method was 
established to help validate the future resumption of our working hypothesis being that eNAD+ is involved in 
extracellular paracrine signalling with implications for various systemic diseases. Moreover, our method facili-
tates the translational research of eNAD+ and its role in aging as well as the pathogenesis of oncologic or other 
systemic diseases by lowering the economic barriers of expensive experimental devices.
Methods
Establishment of the cycling method. The protein alcohol dehydrogenase (ADH, EC1.1.1.1) from 
Saccharomyces cerevisiae was employed to measure the pyridine nucleotides NAD+ and NADH, due to its spec-
ificity for NAD+ as a coenzyme, which, given the cycling nature of the application promotes NADH to the status 
of being a coenzyme as well61. Illustratively, a schematic of the principle behind this cycling assay is provided in 
Fig. 2, where the reader can follow the path of the electrons which are transferred during one cycle of the assay. 
Initially, the NAD+ dependent dehydrogenase ADH catalyses the conversion of ethanol into acetaldehyde (etha-
nal)20, reducing its coenzyme NAD+ to NADH in the process. In turn, this reduced pyridine nucleotide donates 
an electron to the secondary redox indicator dye, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), via a preceding coupled reaction with the primary indicator dye, phenazine methosulfate (PMS). The 
reduction of MTT, and subsequent formation of formazan, can then be assayed colorimetrically and linked to the 
concentration of NAD+ (and NADH).
In order to distinguish NAD+ from NADH, the impeccable works of Lowry et al.62 on ‘The Stability of Pyridine 
Nucleotides’, provided us with a method of extracting the respective nucleotides by means of heat-incubating 
them in different pH milieus. Thereby, NAD+ could be extracted through the addition of a strong acid, destroying 
all NADH molecules, whereas NADH is extracted with a strong base, destroying all NAD+ molecules. The extrac-
tion steps were chosen to feature pH 1.5 for the NAD+ extraction and pH 12.5 for the NADH extraction. In order 
to enzymatically measure the respective pyridine nucleotides, the samples were neutralised at pH 7.4 in order 
to shift the pH into the physiological working range of ADH. The role of r-SBFA in this method was to emulate 
heparinised blood plasma as the standard matrix.
Preparation of chemicals. The assay reaction was initialised, and thus the signal was induced through a 
Master Mix (MM), which, apart from NAD+, contained all the molecules required for the cycling reaction which 
consisted of the following reagents: Alcohol Dehydrogenase from yeast in suspension, EC1.1.1.1 (ADH, SIGMA, 
USA, Catalogue No: 10127558001), thiazolyl blue tetrazolium bromide (MTT, Sigma, USA, Catalogue No: 
M2128), phenazine methosulfate (PMS, Sigma, USA, Catalogue No: P9625), ethanol (100%), Triethanolamine 
(TEA, Sigma, USA, Catalogue No: 90279), and diethyl dicarbonate (DEPC, Sigma, USA, Catalogue No: D5758) 
water. As employed in the MM, the TEA Buffer, as well as the ADH solution were prepared in a ten-fold dilution 
with DEPC water, whilst PMS was prepared as a 10 mg/mL solution and MTT as a 1 mg/mL solution in DEPC 
water. In Table 1, a list of materials is given, featuring the molar make-up of the MM and the respective quantities 
of the molecules employed for a single well (150 μl of MM) and extended to an entire plate (extended to 105 wells, 
to facilitate the use of a pipetting basin). Upon the evaluation of a fluorimetric method, MTT was substituted with 
resazurin (Sigma, USA, Catalogue No: R7017).
The NAD+ and NADH extraction and neutralisation buffers were then prepared in DEPC water, where the 
NAD+ extraction buffer consisted of a 0.3 N HCl solution and the neutralisation buffer comprised equal parts of 
0.36N TEA-HCl (ACROS, USA, Catalogue No: 170051000) and 0.6N KOH. Analogously, 0.3N KOH was used for 
the NADH extraction buffer, whilst the neutralisation buffer was composed of 23% 0.36N TEA-HCl, 23% 0.6N 
Extraction Buffer added (mL) NAD+ extraction (pH) NADH extraction (pH)
0 mL (plasma pH) 7.84 ± 0.05 7.89 ± 0.03
1 mL 4.96 ± 0.06 10.29 ± 0.19
2 mL 3.87 ± 0.05 11.48 ± 0.05
3 mL 2.10 ± 0.03 12.22 ± 0.03
4 mL 1.47 ± 0.02 12.58 ± 0.05
5 mL 1.24 ± 0.01 12.67 ± 0.02
6 mL 1.11 ± 0.01 12.81 ± 0.02
Table 5. Dichotomous pH extraction procedure to extract purified versions of either of the pyridine 
nucleotides, that is, NAD+ or NADH in consideration of Lowry et al.62 and Lilius et al.25 in three fold repetition.
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HCl and 54% DEPC water. PMS and MTT stock solutions were stored in aliquots at −20 °C until use. The MM 
was prepared freshly just prior to measurement to prevent auto-oxidation of PMS and MTT as well as a denatur-
ation of ADH.
Preparation of stock solutions. The linearity, sensitivity, and specificity of the assay was determined 
with β-NAD (Sigma, USA, Catalogue No: N6522) as a reaction standard used for the construction of calibration 
curves. Firstly, a 1 mg/L stock solution of β-NAD in DEPC water was prepared, followed by a thousand-fold 
dilution in DEPC water. Successively the first calibration standard (S1), was obtained to entail a concentration of 
0.5 μg/mL (753.6 nM) by a further one to one dilution of 500 μL in 500 μL DEPC. Afterwards, 5 additional serial 
dilutions constituting 500 μL of previous Standard in 500 μL DEPC water were performed to obtain S2 (376.8 nM) 
through S6 (23.5 nM), respectively, forming a total of six calibration standards, which are summarised in Table 2. 
Initially, two further dilutions were prepared as S7 with a concentration of 11.8nM and S8 with a concentration of 
5.9 nM, however these were excluded from the assay upon evaluation of their suitability as calibration standards. 
Until use, prepared β-NAD aliquots were stored at −80 °C.
Standard matrix preparation. When operating enzymatic assays, and subsequent sample concentration 
extrapolation using calibration curves, it is essential to carry the standards (S1–S6) in a matrix that adequately 
reflects and resembles the physiological properties of human blood plasma, the in vivo matrix of eNAD+. Note 
that, deriving a plasma based standard matrix completely free of NAD+ is not feasible because of the endogenous 
nature of this analyte. For this reason, several commonly used simulated body fluids (SBF) were theoretically 
compared to blood plasma based on their ionic composition and buffering capabilities, and are displayed in 
Table 463. Due to its remarkable ionic resemblance to blood plasma, we employed a revised simulated body fluid 
(r-SBF) to serve as the standard matrix. In addition to that, r-SBF contained HEPES buffer, which features an acid 
dissociation constant of pka = 7.5, thus more closely resembling the buffering nature of plasma than the other-
wise commonly used Tris buffer, exhibiting pka = 8.07. Although the process for finding this standard matrix is 
presented and discussed in the following sections, it was found that the addition of albumin has proven crucial 
in emulating the assay’s enzyme kinetics in human plasma. Finally, a list of materials used to prepare 1000 ml of a 
revised simulated body fluid adjusted with albumin (r-SBFA) in DEPC water is given in Table 3, below. In fact, the 
albumin concentrations of the r-SBFA were evaluated with respect to their impact upon the assay performance at 
0 g/L (r-SBF), 10 g/L, 20 g/L, 30 g/L and 40 g/L. The prepared r-SBFA was stored in aliquots at −20 °C, until use.
Blood sample collection. Human peripheral venous blood from surgical patients, approved by the Charité 
ethics committee (Ethikkommission der Charité Universitätsmedizin Berlin, EA1/291/17 and EA1/018/17), was 
collected - after having obtained informed consent - into lithium heparin, complying with local regulatory guide-
lines and the Declaration of Helsinki. Samples were promptly centrifuged at 2500 g for 15 min at 4 °C in order to 
separate the plasma from all corpuscular parts of the blood, which was successively collected and snap frozen in 
liquid nitrogen. The resulting plasma aliquots were then transferred to a −80 °C freezer, where they were stored 
until being assayed for eNAD+ concentrations. In addition to our own storage time evaluation, literature pro-
vided sufficient evidence that eNAD+ in frozen plasma, as well as the commercially available β-NAD, used in this 
method, were stable under these conditions15,34.
NAD extraction protocol. As previously described, we based the extraction procedure of NAD+ and 
NADH on the findings of Lowry et al.18, adjusted with insights from Lilius et al.25 and O’Reilly et al.13. Heparin 
plasma samples were treated with 0.3N HCl to extract NAD+ and 0.3N KOH to extract NADH, following their 
collection from the −80 °C freezer and after subsequent thawing at room temperature. This is since NAD+ is 
known to be stable for at least half an hour at room temperature15. Initially, 300 μL of sample were transferred 
into a new tube for NAD extraction and 30 μL sample + 270 μL r-SBFA for NADH extraction. Upon addition of 
the acid and base solutions for pyridine nucleotide extraction, the samples were vortexed and then incubated 
at 60 °C for 10 min. Following this, the samples were promptly equilibrated on ice for 10 min. Subsequently, the 
samples were neutralised so as they would exhibit ADH’s optimum working pH of 7.4 through the addition of 
300 μL of their respective neutralisation buffers. The resulting pH values after extraction were confirmed with a 
standard glass pH probe and the data is presented in Table 5. For illustrative purposes, a flowchart of this process 
is depicted in the Supplementary Fig. S.2.
Pipetting and plate reader settings. Before beginning the assaying phase of the method, the MM was 
prepared on ice without MTT, PMS or ADH, in order to prevent auto-oxidation of PMS or MTT and denatura-
tion of ADH. Prior to pipetting the samples into the plate, the neutralised samples were centrifuged at 16.000 g 
for 10 min at 4 °C and the supernatant was successively pipetted into the wells. Standard dilutions (S1 to S6) were 
supplemented with 50 μL of r-SBFA that had been extracted and neutralised in the same manner as the samples, 
to provide the standard matrix similar to human plasma. Analogously, 50 μL of DEPC water was added to the 
samples to be measured in order to simulate the DEPC used in the β-NAD standard dilutions. Subsequently, 
ADH, MTT and PMS were added to the MM, 150 μL of which was pipetted into every well, resuspending twice. 
Afterwards the plate was stored at room temperature in the dark for 5 min prior to assaying. The absorbance of 
the samples was then measured at 565 nm in the microplate reader Infinite® 200 PRO (Tecan, Switzerland) in a 
temperature of 25 °C to prevent significant build-up of bubbles, which occurred at 37 °C. Moreover, the Infinite 
200 PRO further served to assess fluorescence at 590 nm and perform autofluorescence scans. All measurements 
were conducted in duplicates and averaged.
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Enzyme kinetics. Since NAD+ is the coenzyme in the specific reaction between ADH and ethanol, one can 
consider the concentration of NAD+ to be rate limiting as the ethanol concentration was chosen well beyond the 
point of saturation in the MM. NAD+ can therefore be regarded as the new substrate and, consequentially, be 
used in a graphical method to obtain the Michaelis Menten constant, Km, and the maximum reaction velocity, 
vmax, from the double reciprocal Lineweaver-Burke plot described in Lineweaver et al.35. Here, the y-axis is given 
by v−1, and v0 represents the initial reaction velocity and the x-axis is represented by [NAD+]−1, the reciprocal of 
the analyte concentration. The double reciprocal Lineweaver-Burk plot facilitated the graphical evaluation of the 
Michaelis Menten constant, Km, given by the negative reciprocal of the x-axis intercept, in addition to the maxi-
mum reaction velocity, vmax, given by the reciprocal of the y-axis intercept.
Regression analysis. As illustrated shortly, the use of an ordinary regression line not through the origin 
(nTTO, vR = mx + vb), as opposed to a regression line through the origin (TTO, vR = mx + 0), was subject to an 
increased baseline noise and higher eNAD+ estimation bias, introduced by the varying albumin concentrations 
in the standard matrix. Thus, the TTO method allowed for an albumin independent quantification of eNAD+. 
The relative reaction velocity, vR, is made up of the y-axis intersection,vb, and the slope of the absorbance curve, m.
Reliability, reproducibility and linearity. For the sake of evaluating the repeatability and robustness of 
the assay, a quantification of eNAD+ in healthy human heparinised plasma was conducted with eight independ-
ent measurements, featuring the thorough and individual conductance of the complete and previously described 
experimental protocol, including eight independent standard dilutions, as well as eight individually collected 
human heparinised plasma samples from a singular subject. Subsequently, these data were utilised to obtain the 
interval were the enzyme kinetics of the assay reaction occurred in a linear fashion, as well as to confirm the linear 
relationship between the standard β-NAD+ sequential dilutions and their respective relative reaction velocities.
NAD+ storage stability. Being of considerable controversy, the stability of eNAD+ in frozen plasma suf-
fers from a definitive lack of data in the literature. However, upon the conductance of studies involving human 
samples, such knowledge is not only of paramount ethical importance but also crucial for the validity of designed 
experiments, in particular for the algorithm used to store such samples. Therefore healthy human heparinised 
plasma samples were prepared and stored at −80 °C as described above, before being assayed for eNAD+. The 
baseline measurement consisted of an immediate thawing and assaying of the first sample, whilst additional 
measurements were performed up to three months.
Evaluation of a fluorimetric alternative. In consideration of Rhodes et al.20, we explored the ability of 
a fluorimetric method to sense eNAD+ in human heparinised plasma20. For this purpose, we replaced MTT in 
the MM of the colorimetric method with resazurin, which, upon being reduced, forms the highly red fluorescing 
resorufin. Moreover, we paid close attention to conserve the number of moles of resazurin compared to MTT 
participating in the reaction as well as the volume of all suspensions that are part of the MM.
Statistics. Statistical analysis was conducted in Graphpad’s Prism 7 (GraphPad Software, La Jolla, CA, USA). 
Concerning the evaluation of the eNAD+ storage stability, the data were analysed using a two-tailed, paired 
t-test with confidence limits of CL = 99%, as well as a two-way ANOVA (without repeated measures) adjusted 
with Tukey’s multiple comparisons test featuring CL = 99%. The statistical evaluation of the assay’s dependence 
upon the albumin concentration of the standard matrix was conducted using a two-tailed, unpaired t-test with 
the confidence limits of CL = 99%. With regards to the reproducibility of the aforementioned method, signifi-
cance was assessed between two neighbouring standard signals using two different methods, namely a simple, 
two-tailed, unpaired t-test with the confidence limits of CL = 99%, as well as using the more stringent condi-
tions of a two-way ANOVA (without repeated measures) adjusted with Tukey’s multiple comparisons test with 
CL = 99%. Regression analysis of the calibration working curve was performed with the gold standard of an 
ordinary least squares fit, yielding a Pearson Correlation Coefficient, ρ, as well as a coefficient of determination, 
R2, with CL = 99%. Overall, an alpha value of p < 0.01 was applied.
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